Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/10/08  and contains information from public web pages.

Zdravlje Actavis

Wrong Zdravlje Actavis?

Leading Partner

 
Background

Employment History

  • Chief Executive Officer
    Actavis Ltd
  • Consultant
    Actavis Ltd
  • Owner
    Norgesplaster AS
  • Mayor
    Sofia
  • Deputy Chief Executive Officer
    Guðbjörg Edda Eggertsdóttir

Board Memberships and Affiliations

  • Founder
    API R&D
  • Founder
    Decubal
11 Total References
Web References
RSS feed of actavis.com
www.actavis.com, 10 Nov 2008 [cached]
Actavis has received FDA approval of Levetiracetam Extended-Release tablets, a generic equivalent of Keppra XR®. Shipping in the United States commenced immediately following approval. According to IMS Health, Keppra XR® had US total sales of approximately USD161 million for the 12 months ending 30 June 2011. EnquiriesDavid Myers, Jr.Senior Manager, Products & CommunicationsTel: +1 (973) 993 4503E-mail: dmyers@actavis.com Keppra XR ® is a trademark owned by a party other than Actavis.
...
Actavis has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ER® in the United States.
...
Approximately one third of Actavis Group hf’s sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL. Actavis Group hf is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with more than 10,500 employees. Opana ER ® is a trademark owned by a party other than Actavis. Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.
...
The newly launched products include Fosinopril HCT (cardiovascular) and Lisinopril HCT (cardiovascular), both of which were first to market in Bulgaria; Irinotecan (oncology), which Actavis has also recently marketed in the United States; Sertraline (antidepressant) and Bicalutamide (oncology).
...
Actavis today announced the launch of the antiepileptic drug Topiramate in the UK, Germany, France and Switzerland. The product was launched on day one as the originator’s patent expired on 25 September. Actavis was first to market in all four countries. Topiramate is used to treat epilepsy and will be sold in tablets of 25mg, 50mg, 100mg and 200mg. Topiramate is the generic equivalent of Janssen-Cilaq’s Topamax® / Epitomax®. ccording to IMS Health, Janssen-Cilag’s product had sales of approximately €98 mln for the 12 months ended June 2009 in the four countries of UK, Germany, France and Switzerland. Topiramate Actavis was developed by Actavis’ R&D in Iceland and in produced by Actavis in Hafnarfjordur, Iceland. Actavis has already launched Topiramate in other countries where no patent protection was in place, including Portugal in 2007. Product Tue, 29 Sep 2009 06:00:00 GMT {90FEF9E8-7A33-4F8A-B072-175BA0D5FDBF} Actavis launches Finasteride as patent expires in France http://www.actavis.com/en/media+center/newsroom/articles/finasteride+france.htm Actavis launched Finasteride in France on day one, when the originator’s patent expired on Monday 22 June. The distribution of the product has already commenced. Finasteride Actavis was launched by the company under its brand name, and at the same time by various Medis clients. Medis, Actavis‘ Third Party sales division, handles the sales of intellectual property and pharmaceutical products to other pharmaceutical companies in most EU nations and elsewhere and has marketing authorisations in over 50 countries. Finasteride, used for the treatment of prostate cancer, is the generic equivalent of Merck‘s Proscar®. Finasteride Actavis is available in tablets of 5mg in France. Finasteride Actavis was developed by Actavis in Iceland and has already been launched by Actavis and its third party clients in many other European countries and in the United States. Actavis has well over 300 product and market launches on the Group’s various markets to date in 2009.
...
Actavis was awarded the “Innovations in Generics†award at this year’s Pharmacy Business Awards in the United Kingdom, winning the award for the second year in a row.Actavis, the second largest supplier of generic medicine in the UK, has launched up to 165 new products in the past three years; 60 of which were launched in 2009 alone. Actavis’ commitment to day one patent expiries has resulted in numerous day one launches including Lercanidipine and Losartan, with further major patent expiry launches in the pipeline this year.Other outstanding achievements by Actavis in the UK include the introduction of vialshield® hospital packaging, which provides unique safety and protection for vials against breakages and spills. Actavis also focused on providing robust clarity for product labelling and layout with the redesign of Actavis’ hospital packaging and the subsequent launch of “Safety Packagingâ€. Jonathan Wilson, Director at Actavis UK: “Winning the award demonstrates how Actavis is on the cutting edge of innovation when it comes to patient safety and also the ease of use for our products.
...
Actavis has launched Valaciclovir in Switzerland on day one after the patent expired on 27 June. Valaciclovir is used to treat herpes virus infections. Valaciclovir Actavis has already been launched in a number of markets í Europe, including France and the UK, and will soon be entering other European markets. In Switzerland, it was launched under the Actavis brand as well as by customers of Medis - Actavis’ Third-party sales division. Valaciclovir is marketed by GlaxoSmithKline under the brand names Valtrex® / Zelitrex®. The equivalent generic drug from Actavis is available in Switzerland in 500mg tablets. Valaciclovir (also spelt valacyclovir) is used to treat herpes virus infections, including cold sores, shingles and genital herpes in adults as well as chickenpox and cold sores in children. Valaciclovir Actavis was developed by Actavis R&D and is manufactured by Actavis in Iceland.
...
Quinapril will be sold by the division's customers, who will then sell the product under their own brand.Quinapril, is primarily used for the treatment of hypertension in patients with cardiovascular problems, and is manufactured by Actavis in Iceland.
...
Germany is an important market for Actavis and we are confident of making further progress in this region.â€
...
Mr Wessman visited the Zagreb Stock Exchange to discuss the possibility of listing Actavis in Croatia on completion of the acquisition.
...
PLIVA and Actavis compliment each other in almost every respect. They have complimentary geographic coverage, therapeutic focus and a product pipeline with minimal overlap. This will make the integration process very straight forward and the benefits of the combination immediate. PLIVA will be a crucial part of the enlarged Group and its ongoing strategy. We want to encourage the ongoing support of local investors, which is why I have met with the Zagreb Stock Exchange today to ensure that a listing in Croatia is something that Actavis can achieve quickly.
...
Separately, Actavis has entered into a multi-year exclusive agreement with Pfizer for the supply of oncology products.
...
Actavis has received approval from the US Food & Drug Administration to market Epirubicin Hydrochloride Injection. Epirubicin Hydrochloride Injection, the generic to Pfizer’s Ellence®, has been approved in 10 mg / 5 mL, 50 mg / 25 mL, and 200 mg / 100 mL configurations and is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumour involvement following resection of primary breast cancer. Annual US sales of brand and generic Epirubicin HCl Injection were US$17.5 million for the 12 months ending June 2008 according to IMS Health data. Actavis currently markets over 50 hospital products worldwide, with a focus on oncology products and a growing range of anti-infectives, local anesthetics and analgesics. Epirubicin HCl Injection, is developed by Actavis scientists in Romania. It's Actavis' second injectable oncology product in the United States; Actavis received FDA approval for Irinotecan Hydrochloride Injection in February. Product Mon, 06 Oct 2008 05:00:00 GMT {9893F2CD-CFD2-447E-9AFD-3A1FABF3B66F} Pilocarpine Actavis tablets US http://www.actavis.com/en/media+center/newsroom/articles/Pilocarpine+Tablets+US.htm Actavis has begun shipping Pilocarpine Hydrochloride 7.5mg tablets in the U.S., to complement Pilocarpine 5mg tablets that the company currently offers in the U.S. Pilocarpine Tablets are used to treat dryness of the mouth and throat caused by a decrease in the amount of saliva that may occur after radiation treatment for cancer of the head and neck or in patients with Sjogren's syndrome.
...
Actavis has acquired a 90% share in Zhejiang Chiral Medicine Chemicals Company for an undisclosed amount. Strategic RationaleChiral is specialized in research, development and production of active pharmaceutical ingredients (APIs). The acquisition is part of Actavis’ strategy to get direct access to low cost API manufacturing. Actavis has already established an API R&D centre in India with a pipeline of 70 products.
...
In addition to building up a strategic position in APIs, Actavis produces generic pharmaceuticals at 21 production sites in 13 countries, with an annual capacity of 24 bn tablets and capsules. In China, Actavis operates a manufacturing site in Guangdong, which produces tablets, capsules, suspensions, solutions, creams and ointments. Af
RSS feed of actavis.com
www.actavis.com, 27 Feb 2008 [cached]
Sigurdur Oli Olafsson joined Actavis in 2003, after working for Pfizer UK from 1998 and moving to Pfizer US in 2001 to take a post in Global Research and Development.
...
Actavis is now in a solid position as a major global generic pharmaceutical player.
...
Actavis has signed an exclusive distribution and packaging agreement for a number of generic products with Laboratoire Pharmaceutique Algérien (LPA), an Algerian owned and operated pharmaceutical company, headquartered in Algiers. The agreement with LPA, one of the leading pharmaceutical companies in Algeria, is an important stepping stone for the entrance of Actavis in this fast-growing market. The Algerian pharmaceutical market is the third-largest in Africa after Egypt and South Africa. Commenting on this partnership, Hordur Thorhallson, Executive Vice President Emerging Markets, Actavis said: “The progress that the regional office in Malta has achieved so far is very promising and this enhances the role of this office as a regional hub for North, Central and West Africa†Mr Ait Adjedjou, President, LPA said that he was very pleased that LPA had signed on with a world leader such as Actavis and said that the investment that his company was laying out had to be taken into context, in the sense that the world was in a global slowdown, yet the investment was still going ahead. Also present at the contract signing ceremony were Mr Daniel Vella Friggieri â€" Regional Director North, Central and West Africa, Actavis and Mr Guillaume Tornadre â€" Operations Director, LPA.
...
Summary of joint companyName: Actavis ASKA K.K.Head Office: TokyoCapital: 200 million Yen (planned)Investment ratio: ASKA: 55%, Actavis: 45%Establishment: 1 April 2009 (planned)
...
Actavis has the opportunity to enter the Japanese market and utilize its wide product portfolio, both existing and in the pipeline, in co-operation with an experienced and resourceful partner.
...
Thus, the new joint company will be able to maximize the different and complementary strengths of its founders, and will aim to become a leading company in the Japanese generic products’ market.†Sigurdur Oli Olafsson, CEO, Actavis Group:“This is an excellent opportunity for Actavis to enter the Japanese market - the second biggest pharmaceutical market in the world.
...
Summary of joint companyName: Actavis ASKA Co., Ltd.Head Office: TokyoCapital: 200 million Yen (planned)Investment ratio: ASKA: 55%, Actavis: 45%Establishment: April 2009 (planned)
...
Actavis has announced that three new construction projects are underway at Actavis in India.
...
Zdravlje Actavis in Serbia has been formally presented with certificates for the international standards ISO 9001:2000 (quality) and ISO 14001 (environment), as well as OHSAS 18001 (occupational health and safety) by the authorised certification house, SGS. The certification ceremony was held in Belgrade. Goran Stojilković, Managing director Zdravlje Actavis:“Great teamwork and the efforts of all our employees have brought our company to the highest European quality, environmental and health- and safety standards.
...
Awarded for the most innovative and successful new product launch or ‘Pom to P’ (prescription to OTC/without prescription) switch, Clamelle from Actavis was a clear winner as the first OTC oral antibiotic (azithromycin 500mg), as well as being supplied as part of a professional service and a diagnostic test.
...
Actavis has built a ramp for the access of disabled people to a major cathedral in Bulgaria.
...
Actavis awarded for cultural and social merits During the ceremony Mrs Donna Steiger, Chairman of the International Tribunal of crimes against humanity in the area of disabled people awarded Actavis for “Contribution for global development and special merits for cultural and social priorities for 2008â€.
...
Actavis awarded for cultural and social merits During the ceremony Mrs Donna Steiger, Chairman of the International Tribunal of crimes against humanity in the area of disabled people awarded Actavis for “Contribution for global development and special merits for cultural and social priorities for 2008â€.
...
First ramp in SofiaWith the ramp opening in Varna, Actavis continues its national campaign called “Architecture Accessibility for Disabled People to Bulgaria’s Spiritual Symbolsâ€. The campaign was launched last year with the opening of the first ramp to the Alexander Nevski Cathedral in Sofia.
...
Mr Wessman visited the Zagreb Stock Exchange to discuss the possibility of listing Actavis in Croatia on completion of the acquisition.
...
PLIVA and Actavis compliment each other in almost every respect. They have complimentary geographic coverage, therapeutic focus and a product pipeline with minimal overlap. This will make the integration process very straight forward and the benefits of the combination immediate. PLIVA will be a crucial part of the enlarged Group and its ongoing strategy. We want to encourage the ongoing support of local investors, which is why I have met with the Zagreb Stock Exchange today to ensure that a listing in Croatia is something that Actavis can achieve quickly.
...
The Group donates EUR40,000 to the city of Sofia over the next five years to support the project in partnership with ECAD. “I would like to thank Actavis for the support regarding this programme as well as for its contribution for helping the Municipality like in other projects like the garden restoration project†the Mayor of Sofia said during the event. he signing ceremony held at the prestigious Sheraton hotel, caused a surge of publicity. The event was attended by the Deputy Minister of education, over 30 journalists and representatives of non-governmental organizations and local communities. The ceremony was followed by a reception. Commitment Tue, 11 Jul 2006 00:14:00 GMT {9509F8CD-55A8-4566-B077-4FC113F7E081} Alprazolam ER approval in the U.S. for Actavis http://www.actavis.com/en/media+center/newsroom/articles/alprazolam+us.htm Actavis today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam ER tablets.
...
Fentanyl patches sold by Actavis in Europe are not affected by this recall. The 14 lots of Fentanyl transdermal system patches being recalled may have a fold-over defect which has the potential to cause the patch to leak fentanyl gel, therefore, as a precaution, Actavis is recalling these lots.
...
The patches are double-branded, with Abrika on the pouch and Actavis on the box. Affected patches should not be handled directly.
...
Actavis and Vilnius, the capital of Lithuania, have signed a sponsorship agreement supporting Vilnius’ participation in a pan-European drug prevention programme.
...
The city of Reykjavík serves as the chair of the programme and Actavis is the programme’s main sponsor.
...
Actavis has received approval from the U.S. Food & Drug Administration to market Meloxicam Tablets. Distribution of the product has already started. Meloxicam Tablets, the generic equivalent of Boehringer Ingelheim’s Mobic® Tablets, are available in both 7.5 mg and 15 mg strengths. Meloxicam is used to treat signs and symptoms of osteoarthritis and rheumatoid arthritis. Annual brand sales of Meloxicam Tablets in the U.S. were approximately US$1.1 billion for the full year 2005. In the US alone, Actavis expects to launch 15 new products in 2006, in addition to filing 30 ANDAs. The company’s US operations are located in New Jersey, Maryland and North Carolina. Product Thu, 03 Aug 2006 20:06:00 GMT {F53B1740-CF3C-4DDE-AB0D-E3A94BFC3A48} HCTZ new strength Actavis US http://www.actavis.com/en/media+center/newsroom/articles/hctz+new+strength+us.htm Actavis has received approval from the U.S. Food & Drug Administration to market Hydrochlorothiazide Tablets USP, 12.5 mg.
...
Actavis is a major sponsor of the European Figure Skating Championship taking place in Warsaw, Poland from 22 â€" 28 January 2007.
...
Actavis announced today that it has received a warning letter from the U.S. Food and Drug Administration (FDA), related to its inspection of the Group's solid oral dose manufacturing facility in Little Falls, New Jersey. The Warning Letter identifies deficiencies in the way that Actavis has handled its adverse medical event reporting obligations. The Warning Letter also questions the marketing status of certain of Actavis's older products that are currently being marketed by the Group relying on pre-ANDA drug approval mechanisms ("Older Drugs"). Since the inspection, Actavis has materially revised its adverse drug event and pharmacovigilence procedures to address certain deficiencies and to establish a system that ensures continuous compliance with regulatory expectations. The Group has also complied with all previous adverse medical event-reporting obligations that were over due or deficient. Management is confident that each of the identified Older Drugs are currently being marketed in accordance with applicable regulations, but is undertaking a full review of these products to add
RSS feed of actavis.com
www.actavis.com, 27 Feb 2008 [cached]
Actavis is a major sponsor of the European Figure Skating Championship taking place in Warsaw, Poland from 22 â€" 28 January 2007.
...
Actavis launched Pantoprazole tablets in Germany, Ireland, and the Netherlands as the patent expired on 6 May. This is Actavis Group’s first own brand launch of this molecule. In Germany and the Netherlands, the product was also launched by Actavis’ third party sales division’s (Medis’) customers at the same time. Earlier this year, Medis’ customers launched the product in Hungary and Poland. Pantoprazole, a proton pump inhibitor (PPI), is used to treat acid-related stomach and throat problems, including acid reflux (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Pantoprazole Actavis is the generic equivalent of Wyeth‘s Protonix®. Pantoprazole Actavis is available in 20mg and 40mg tablets. The product was developed by Actavis R&D in Iceland, and manufactured by Actavis Malta.
...
Actavis today announced the launch of the antiepileptic drug Topiramate in the UK, Germany, France and Switzerland. The product was launched on day one as the originator’s patent expired on 25 September. Actavis was first to market in all four countries. Topiramate is used to treat epilepsy and will be sold in tablets of 25mg, 50mg, 100mg and 200mg. Topiramate is the generic equivalent of Janssen-Cilaq’s Topamax® / Epitomax®. ccording to IMS Health, Janssen-Cilag’s product had sales of approximately €98 mln for the 12 months ended June 2009 in the four countries of UK, Germany, France and Switzerland. Topiramate Actavis was developed by Actavis’ R&D in Iceland and in produced by Actavis in Hafnarfjordur, Iceland. Actavis has already launched Topiramate in other countries where no patent protection was in place, including Portugal in 2007.
...
The “pilot-scale†production building is part of a wider EUR13 million-investment in facilities for R&D, Quality and Operations that will ensure Actavis is able to develop a broader range of products in a very efficient manner. The goal is to condense the division’s operations into one location. Within the next 12 months the remainder of R&D functions including the laboratories, analytical development units and patent department will also be on site. The modern facility will enable Actavis in Iceland to produce a wider range of products than ever before.
...
The plant is operated by Indian pharmaceutical company Emcure, which has concluded a collaboration agreement with Actavis.
...
Actavis announced today that it is expanding its sales network with a new office in Mongolia. The company has begun selling direct to distributors in the country. The new Actavis office is located in the Mongolian capital, Ulaanbaddar. The office will officially open on 13 September 2004.
...
Actavis currently has 38 products registered for the Mongolian market. A large international exhibition of medical equipment and pharmaceuticals will be held in Ulaanbaddar in September. Actavis will be active participants and taking the opportunity to promote the Group's new name for the first time in Mongolia.
...
The products, manufactured by Actavis, are distributed by Mylan Pharmaceuticals, Inc. under the "Bertek" label and by UDL Laboratories, Inc. under the "UDL" label. Acting together with Actavis to enact the recall of the product, Mylan Pharmaceuticals, Inc. as the distributor of Digitek, retained Stericycle customer service centre (tel. 1-888-276-6166) to act as the recall coordinator immediately following Actavis’ decision to recall the product. Consumers are asked to direct all enquiries they may have regarding this recall to Stericycle for proper handling and distribution. Representatives at the service center are available to support all consumer queries and to provide direction on how to return the product. If you have any questions about your treatment, or any medical inquiries regarding the product or possible substitutes, you should contact your physician immediately. For further information, please visit Actavis' United States website: Frequently asked questions Press release from 25 April
...
Actavis today announced that Robert Wessman, Actavis’ President & CEO, will discuss “The strategy and competitiveness of Actavis in a fiercely competitive environment†at the annual UBS Global Specialty and Generic Pharmaceuticals Conference on Wednesday, 28 May 2008.
...
Actavis today announced that Robert Wessman, Actavis’ President & CEO, will discuss “The strategy and competitiveness of Actavis in a fiercely competitive environment†at the annual UBS Global Specialty and Generic Pharmaceuticals Conference on Wednesday, 28 May 2008.
...
Awarded for the most innovative and successful new product launch or ‘Pom to P’ (prescription to OTC/without prescription) switch, Clamelle from Actavis was a clear winner as the first OTC oral antibiotic (azithromycin 500mg), as well as being supplied as part of a professional service and a diagnostic test.
...
Summary of joint companyName: Actavis ASKA K.K.Head Office: TokyoCapital: 200 million Yen (planned)Investment ratio: ASKA: 55%, Actavis: 45%Establishment: 1 April 2009 (planned)
...
Actavis' CEO, Sigurdur Oli Olafsson, was keynote speaker at the FT Global Pharmaceutical & Biotechnology Conference 2009, in London on 18 November. In his presentation, "Transformation through collaboration - Increasing collaboration of originators & generics," he discussed his view of the future of an industry on the move, with generics and emerging markets in the midst of the growth strategy. With its business model designed for constant improvement of cost efficiencies, he said, the generics industry is more recession proof than most. Stefan Jokull Sveinsson, Actavis' EVP Research and development, was keynote speaker at the World Generic Medicines Congress Americas 2009, in Washington DC on 18 November.
...
Actavis is one of the leading generic pharmaceutical manufacturers in the world. Actavis has been rapidly expanding its presence in the hospitals market and has a range of injectable products in addition to a comprehensive oncology range comprising over 30 molecules. Bioluz is a fully integrated drug manufacturer focused on premixed drugs in flexible bags and is part of the Technoflex group - European leader in design and production of infusion bags and connectors. Bioluz is the only European independent CMO to offer aseptic filling of IV drugs in sterile flexible bags. James Burt, Global Director of Actavis’ Hospital Unit commented: “The contract with Bioluz signifies an important development for our hospitals business, as it enables us to provide further diversity in our product offering and a strong foothold in the fast growing market for IV drugs in ready to use format.“ Jean-Jacques Chappaz, Bioluz CEO commented: “The deal signed with Actavis is in line with our will to partner with the major pharmaceutical companies.
...
Actavis today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market. The product, Atorvastatin Magnesium, is launched by four of Spain’s largest generic pharmaceutical companies. Distribution of the product to Spanish pharmacies has already commenced. Atorvastatin efficiently regulates the blood cholesterol levels and is one of the most effective drugs used in the therapy of primary hypercholesterolemia. Atorvastatin Magnesium is produced by Actavis in 10mg, 20mg and 40mg tablets.
...
The Clamelle Chlamydia service is run jointly by Actavis, the NPA and Gordon Laboratory Group (GLG), a private laboratory which carries out the gold standard Nucleic Acid Amplification Technique (NAAT) testing, manages the test results and the Clamelle customer database.
...
Actavis has launched its Isotretinoin under the brand name Decutan into the United Arab Emirates and Iran.
...
The launch of Decutan marks the entry of Actavis onto the Middle East markets.
...
Actavis are pleased to announce the launch of 6 new generic products in the first 6 weeks of 2009 to start what promises to be an exciting year for the company in the United Kingdom.All new products have been launched in Actavis packaging that has been carefully designed to maximise safety and compliance.
...
Actavis has received approval from the US Food & Drug Administration (FDA) to market Levetiracetam Oral Solution. Distribution of the product has commenced.
...
Milan Todorovic, Actavis' Executive Vice President Central Eastern Europe, was keynote speaker on globalisation and integration.
...
Actavis has made more than 20 acquisitions in recent years, while maintaining strong organic growth.
...
Supporting local children left homeless and helping to tackle the threat of Dengue fever are among the community initiatives recently undertaken by Actavis in Indonesia. On April 13 the local Actavis management team presented a cheque for USD 7,500 to the Director of SOS Children’s Villages Indonesia, part of the international child welfare charity.
RSS feed of actavis.com
www.actavis.com, 27 Feb 2008 [cached]
Claudio Albrecht, CEO Actavis:“The site is 100% powered by geothermal energy, and is therefore the most eco-friendly pharmaceutical facility in the world.
...
Actavis operates 14 manufacturing sites in 12 different countries: US, Bulgaria, Iceland, China, Italy, India, Indonesia, Malta, Romania, Russia, Serbia, and the UK.
...
Before the distinguished guests departed, Robert Wessman presented President Kalam with a gift from Actavis, a sculpture by an Icelandic artist.
...
Sigurdur Oli Olafsson joined Actavis in 2003, after working for Pfizer UK from 1998 and moving to Pfizer US in 2001 to take a post in Global Research and Development.
...
Actavis is now in a solid position as a major global generic pharmaceutical player.
...
Actavis announced today that it is expanding its sales network with a new office in Mongolia. The company has begun selling direct to distributors in the country. The new Actavis office is located in the Mongolian capital, Ulaanbaddar. The office will officially open on 13 September 2004.
...
Actavis currently has 38 products registered for the Mongolian market. A large international exhibition of medical equipment and pharmaceuticals will be held in Ulaanbaddar in September. Actavis will be active participants and taking the opportunity to promote the Group's new name for the first time in Mongolia.
...
The news agency quotes him as saying that Actavis is not in an ideal position when it comes to enterprise value, but adds that after two to three years an initial public offering (IPO), a sale or a tie-up with another company could become an option. Handelsblatt focuses on possible acquisitions in markets where the company is underrepresented, including Poland, Russia, Turkey and Southern-Europe. The paper says Stada is not on Actavis’ radar, as its main strength is Germany, a market that’s not attractive at the moment due to pricing pressures. English:Actavis Is Looking for Acquisitions, Chief Tells Handelsblatt (Bloomberg)Actavis to boost its M&A appeal in 2-3 years (Reuters) German:Actavis Will Konsolidierung der Generikabranche vorantreiben (Reuters TV interview)Isländischer Generikakonzern Actavis plant Zukäufe (Handelsblatt)
...
Anastrozole Actavis is the generic equivalent of AstraZeneca‘s brand product Arimidex® The brand sold for EUR492 million in Europe for the twelve month period ended September 2010. (IMS Health).
...
Actavis today announced the launch of Risedronate in four countries in Europe, immediately after the patent expired. Actavis launched the generic equivalent of Warner Chilcott‘s Actonel® under its own brand on day one in Germany, France, the United Kingdom and Ireland.
...
Risedronate from Actavis is available in 35mg tablets. The product is developed and produced by Actavis in Iceland.
...
Only the large generic players such as Teva, Sandoz, Mylan and Actavis have the capability to do this, either by themselves or in partnerships with originators. We want to be selective with our biologic target portfolio. Endocrinology (a branch of biology and medicine dealing with the endocrine system) is one of the most interesting growth areas in the pharmaceutical industry. Actavis now offers a broad selection of oral diabetic medicines, so the addition of insulin and later insulin analogue is thus rational for Actavis and one of the areas we are looking towards. Actavis is also one of the leading suppliers of generic oncology products, with a wide selection of products used in chemotherapy.
...
Actavis has received approval from the FDA to market Zolpidem Tartrate Extended-Release Tablets, USP 6,25mg CIV in the United States. Distribution of the product has commenced. As the first company to file an ANDA that contained a paragraph IV certification for Ambien® CR 6,25mg, Actavis has been awarded 180-day exclusivity to market this product.
...
Actavis has launched Valaciclovir in Switzerland on day one after the patent expired on 27 June. Valaciclovir is used to treat herpes virus infections. Valaciclovir Actavis has already been launched in a number of markets í Europe, including France and the UK, and will soon be entering other European markets. In Switzerland, it was launched under the Actavis brand as well as by customers of Medis - Actavis’ Third-party sales division. Valaciclovir is marketed by GlaxoSmithKline under the brand names Valtrex® / Zelitrex®. The equivalent generic drug from Actavis is available in Switzerland in 500mg tablets. Valaciclovir (also spelt valacyclovir) is used to treat herpes virus infections, including cold sores, shingles and genital herpes in adults as well as chickenpox and cold sores in children. Valaciclovir Actavis was developed by Actavis R&D and is manufactured by Actavis in Iceland. Product Wed, 30 Jun 2010 21:45:00 GMT {0E449062-F3F4-490B-85D5-7BC04BD9B0DB} Actavis opens Beijing office http://www.actavis.com/en/media+center/newsroom/articles/beijing_office_opens.htm Actavis has established a regional office for China at Beijing's Youth Plaza Office Building. Actavis' Beijing office will primarily handle registrations for imported products and related regulatory issues, as well as sales activities. The Beijing office will be responsible for further developing Actavis' business in China. The Company is already established in Guangzhou in Guangdong province, where it operates a manufacturing site. About 80% of Actavis' sales in China have been in Guangdong, but the company‘s ambitious plans for growth in the Chinese market over the coming years include an expansion into other provinces, with the addition of the Beijing office as a first step. The Beijing office is located on the Third Ring Road which is the busiest section of the Central Business District in the Chinese capital. The Actavis (Foshan) Pharmaceutical Co., Ltd. is a joint venture between the Actavis Group and Foshan Chanbende Development Co., Ltd. The Guangdong manufacturing site employs 300 people producing antibiotics and other products, particularly for use in the treatment of the digestive and cardiovascular system. Contact details for Actavis in China
...
Dr. Claudio Albrecht has been appointed as CEO of Actavis, with immediate effect.
...
His departure follows seven years in senior management roles during which time Actavis has grown exponentially to become one of the world’s leading generics companies. Following a number of acquisitions over the last decade, Actavis’ senior management is currently spread across five different countries. A search is underway to find a central location where the senior team can be based in one place. Iceland will remain a key site for manufacturing, research & development and Medis, the third-party sales division. Thor Bjorgolfsson, founder and chairman Actavis Group, said:“I am delighted that we have attracted someone of Dr. Claudio Albrecht’s calibre to Actavis.
...
I would like to thank Sigurdur Oli Olafsson for his pivotal role in keeping Actavis a strong and robust company through difficult years.†Sigurdur Oli Olafsson said:“Despite the economic turbulence of the last few years, Actavis has continued to grow and significantly strengthen its performance in key markets, including the US.
...
Actavis has one of the best R&D pipelines in the industry, but we still need to grow our market presence in many of the big markets.
...
Actavis today announced the launch of Mycofenolatmofetil Actavis, immediately after the patent expired in the UK, Netherlands, Germany, Sweden, and Finland. Mycofenolatmofetil Actavis (mycophenolate mofetil) is the generic equivalent of Roche’s Cellcept®. It is used with other medicines to lower the body’s immunity after heart, kidney or liver transplant. Mycofenolatmofetil Actavis is available in 500mg tablets or 250mg capsules. Annual brand product sales in Europe were about EUR400 million, for the 12 months ending June 2010 (IMS data). Actavis has already launched the product in Bulgaria, Iceland, Norway, Portugal, Romania and Slovakia, where no patent was in place.
...
Actavis today announced the launch of a Docetaxel single vial, immediately after the patent expired in major European markets. The cancer drug was launched by Actavis under its own brand in Germany, the Netherlands, UK and Sweden, as well as by Medis ― the company’s sales division to third-party clients ― in the UK and Germany. Actavis has also launched the Docetaxel single vial in Ireland, Finland, Portugal and Austria which were patent-free. The product will be launched across Europe â€" patents permitting - during 2010 and 2011. Furthermore, Actavis has launched a Docetaxel twin vial in Romania, the Ukraine and in the Balkans. Docetaxel is used to treat a range of different cancers including advanced breast cancer, lung cancer, prostate cancer and stomach cancer. The Docetaxel single vial is produced by Actavis in 20mg, 80mg and 140mg vial sizes. Docetaxel Actavis is the generic equivalent of the Taxotere® brand product from Sanofi Aventis. The brand product, Taxotere® had sales across 29 countries in Europe of approximately EUR800 million for the 12 months ending 30 June 2010, according to IMS Health The Doce
RSS feed of actavis.com
www.actavis.com, 27 Feb 2008 [cached]
Claudio Albrecht, CEO Actavis:“The site is 100% powered by geothermal energy, and is therefore the most eco-friendly pharmaceutical facility in the world.
...
Actavis operates 14 manufacturing sites in 12 different countries: US, Bulgaria, Iceland, China, Italy, India, Indonesia, Malta, Romania, Russia, Serbia, and the UK.
...
Actavis today announced the launch of Risedronate in four countries in Europe, immediately after the patent expired. Actavis launched the generic equivalent of Warner Chilcott‘s Actonel® under its own brand on day one in Germany, France, the United Kingdom and Ireland.
...
Risedronate from Actavis is available in 35mg tablets. The product is developed and produced by Actavis in Iceland.
...
Only the large generic players such as Teva, Sandoz, Mylan and Actavis have the capability to do this, either by themselves or in partnerships with originators. We want to be selective with our biologic target portfolio. Endocrinology (a branch of biology and medicine dealing with the endocrine system) is one of the most interesting growth areas in the pharmaceutical industry. Actavis now offers a broad selection of oral diabetic medicines, so the addition of insulin and later insulin analogue is thus rational for Actavis and one of the areas we are looking towards. Actavis is also one of the leading suppliers of generic oncology products, with a wide selection of products used in chemotherapy.
...
Actavis has received approval from the FDA to market Zolpidem Tartrate Extended-Release Tablets, USP 6,25mg CIV in the United States. Distribution of the product has commenced. As the first company to file an ANDA that contained a paragraph IV certification for Ambien® CR 6,25mg, Actavis has been awarded 180-day exclusivity to market this product.
...
Actavis has launched Valaciclovir in Switzerland on day one after the patent expired on 27 June. Valaciclovir is used to treat herpes virus infections. Valaciclovir Actavis has already been launched in a number of markets í Europe, including France and the UK, and will soon be entering other European markets. In Switzerland, it was launched under the Actavis brand as well as by customers of Medis - Actavis’ Third-party sales division. Valaciclovir is marketed by GlaxoSmithKline under the brand names Valtrex® / Zelitrex®. The equivalent generic drug from Actavis is available in Switzerland in 500mg tablets. Valaciclovir (also spelt valacyclovir) is used to treat herpes virus infections, including cold sores, shingles and genital herpes in adults as well as chickenpox and cold sores in children. Valaciclovir Actavis was developed by Actavis R&D and is manufactured by Actavis in Iceland. Product Wed, 30 Jun 2010 21:45:00 GMT {0E449062-F3F4-490B-85D5-7BC04BD9B0DB} Actavis opens Beijing office http://www.actavis.com/en/media+center/newsroom/articles/beijing_office_opens.htm Actavis has established a regional office for China at Beijing's Youth Plaza Office Building. Actavis' Beijing office will primarily handle registrations for imported products and related regulatory issues, as well as sales activities. The Beijing office will be responsible for further developing Actavis' business in China. The Company is already established in Guangzhou in Guangdong province, where it operates a manufacturing site. About 80% of Actavis' sales in China have been in Guangdong, but the company‘s ambitious plans for growth in the Chinese market over the coming years include an expansion into other provinces, with the addition of the Beijing office as a first step. The Beijing office is located on the Third Ring Road which is the busiest section of the Central Business District in the Chinese capital. The Actavis (Foshan) Pharmaceutical Co., Ltd. is a joint venture between the Actavis Group and Foshan Chanbende Development Co., Ltd. The Guangdong manufacturing site employs 300 people producing antibiotics and other products, particularly for use in the treatment of the digestive and cardiovascular system. Contact details for Actavis in China
...
Dr. Claudio Albrecht has been appointed as CEO of Actavis, with immediate effect.
...
His departure follows seven years in senior management roles during which time Actavis has grown exponentially to become one of the world’s leading generics companies. Following a number of acquisitions over the last decade, Actavis’ senior management is currently spread across five different countries. A search is underway to find a central location where the senior team can be based in one place. Iceland will remain a key site for manufacturing, research & development and Medis, the third-party sales division. Thor Bjorgolfsson, founder and chairman Actavis Group, said:“I am delighted that we have attracted someone of Dr. Claudio Albrecht’s calibre to Actavis.
...
I would like to thank Sigurdur Oli Olafsson for his pivotal role in keeping Actavis a strong and robust company through difficult years.†Sigurdur Oli Olafsson said:“Despite the economic turbulence of the last few years, Actavis has continued to grow and significantly strengthen its performance in key markets, including the US.
...
Actavis has one of the best R&D pipelines in the industry, but we still need to grow our market presence in many of the big markets.
...
Actavis today announced the launch of Mycofenolatmofetil Actavis, immediately after the patent expired in the UK, Netherlands, Germany, Sweden, and Finland. Mycofenolatmofetil Actavis (mycophenolate mofetil) is the generic equivalent of Roche’s Cellcept®. It is used with other medicines to lower the body’s immunity after heart, kidney or liver transplant. Mycofenolatmofetil Actavis is available in 500mg tablets or 250mg capsules. Annual brand product sales in Europe were about EUR400 million, for the 12 months ending June 2010 (IMS data). Actavis has already launched the product in Bulgaria, Iceland, Norway, Portugal, Romania and Slovakia, where no patent was in place.
...
Actavis today announced the launch of a Docetaxel single vial, immediately after the patent expired in major European markets. The cancer drug was launched by Actavis under its own brand in Germany, the Netherlands, UK and Sweden, as well as by Medis ― the company’s sales division to third-party clients ― in the UK and Germany. Actavis has also launched the Docetaxel single vial in Ireland, Finland, Portugal and Austria which were patent-free. The product will be launched across Europe â€" patents permitting - during 2010 and 2011. Furthermore, Actavis has launched a Docetaxel twin vial in Romania, the Ukraine and in the Balkans. Docetaxel is used to treat a range of different cancers including advanced breast cancer, lung cancer, prostate cancer and stomach cancer. The Docetaxel single vial is produced by Actavis in 20mg, 80mg and 140mg vial sizes. Docetaxel Actavis is the generic equivalent of the Taxotere® brand product from Sanofi Aventis. The brand product, Taxotere® had sales across 29 countries in Europe of approximately EUR800 million for the 12 months ending 30 June 2010, according to IMS Health The Docetaxel single vial is manufactured by Actavis in Romania.
...
Actavis also brings to market the unique 140mg vial size which is designed to be more convenient and reduce wastage.â€
...
Actavis was awarded the “Innovations in Generics†award at this year’s Pharmacy Business Awards in the United Kingdom, winning the award for the second year in a row.Actavis, the second largest supplier of generic medicine in the UK, has launched up to 165 new products in the past three years; 60 of which were launched in 2009 alone. Actavis’ commitment to day one patent expiries has resulted in numerous day one launches including Lercanidipine and Losartan, with further major patent expiry launches in the pipeline this year.Other outstanding achievements by Actavis in the UK include the introduction of vialshield® hospital packaging, which provides unique safety and protection for vials against breakages and spills. Actavis also focused on providing robust clarity for product labelling and layout with the redesign of Actavis’ hospital packaging and the subsequent launch of “Safety Packagingâ€. Jonathan Wilson, Director at Actavis UK: “Winning the award demonstrates how Actavis is on the cutting edge of innovation when it comes to patient safety and also the ease of use for our products.
...
Actavis has received approval from the United States Food & Drug Administration (FDA) to market Atomoxetine HCl capsules for the treatment of ADHD (attention deficit / hyperactivity disorder). No release date has been set for Atomoxetine, Actavis’ generic equivalent to Eli Lilly and Company’s Strattera®. The US Court of Appeals for the Federal Circuit is reviewing a ruling from 12 August that invalidated Lilly’s patent, which is due to expire in 2017. Actavis intends to market Atomoxetine HCl in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg strengths.
...
Actavis today announced that it has received approval from the FDA to market Bupropion HCl Extended-Release (SR) tablets 100mg and 200mg.
...
Bupropion HCl SR Tablets, the generic
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.